Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.38 |
| ▸ | CTSG | P08311 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 4/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CHAT | P28329 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6390031 | 0.92 | ELANE (0.40) | ELANECTSGTYMSMEN1KMT2A | |
| SCHEMBL6394483 | 0.90 | TYMS (0.34) | LMNATYMSSNCACHAT | |
| SCHEMBL6390530 | 0.84 | ELANE (0.39) | ELANECTSGTYMSSNCA | |
| SCHEMBL6388290 | 0.83 | ELANE (0.37) | ELANECTSGHPGDTYMS | |
| SCHEMBL6391678 | 0.81 | TYMS (0.42) | TYMSSNCACHATMEN1POLB | |
| SCHEMBL6391690 | 0.77 | SNCA (0.37) | ELANECTSGTYMSSNCACHAT | |
| SCHEMBL6394520 | 0.76 | TYMS (0.34) | LMNAHPGDHIF1AHSD17B10TYMS | |
| SCHEMBL6393874 | 0.76 | ELANE (0.35) | ELANECTSGLMNAHSD17B10TYMS | |
| SCHEMBL6387036 | 0.76 | ELANE (0.39) | ELANECTSGTYMS | |
| SCHEMBL6390026 | 0.75 | TYMS (0.35) | HPGDTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050040373-A1 | Dopant and conductive polymer material therewith | MITSUI CHEMICALS, INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-6814888-B2 | FOR PRODUCING SOLID ELECTROLYTIC CAPACITOR | MITSUI CHEMICALS, INC. (JP) | 2004-11-09 | — | — | US | disclosed |
| US-20030142462-A1 | Dopant agent and electroconductive polymer material comprising the same | MITSUI CHEMICALS, INC. (JP) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030142462-A1 | Dopant agent and electroconductive polymer material comprising the same | RPS6, H1-10, H1-0 | ELANE 2335/4885CTSG 2871/4885LMNA 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.